All In Biotech

Drug Trial Radar · NCT01065857

Safety and Efficacy Study of CitraFleet (Sodium Picosulphate) as an Evacuating Treatment Prior to Colonoscopy.

Phase III, Multicenter, Randomized, Assessor-blind Study to Evaluate the Safety and Efficacy of CitraFleet (Sodium Picosulphate) as an Evacuating Treatment Prior to Colonoscopy.

Last checked: Nov 19, 2026Latest source record: Apr 15, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 547 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

547

Planned (sponsor's estimate)

Start

Jan 2010

Primary completion

Jun 2010

Study completion Feb 2011

Sponsor

Sponsor type
Industry
Collaborators
Trial Form Support S.L.; Apices Soluciones S.L.
First posted
Feb 9, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine any significant differences in the efficacy and acceptability between CitraFleet and Klean Prep® (polyethylene glycol) for the preparation of gastrointestinal subjects undergoing a colon examination.

Conditions

  • Subjects Undergoing a Complete Exploratory Diagnostic Colonoscopy for the First Time.

Interventions

  • Sodium picosulphate, light magnesium oxide and anhydride citric acid.Drug

    2 Single-dose sachets containing sodium picosulphate (0.01g/sachet), light magnesium oxide (3.50g/sachet) and anhydrous citric acid (10.97g/sachet).

  • Polyethylene glycol, KCl, NaCl, sodium sulphate anhydrous and sodium bicarbonate.Drug

    4 sachets containing Polyethylene glycol 3350 (59 gr), KCl (0.7425 gr), NaCl (1.465 gr), sodium sulphate anhydrous (5.685 gr), sodium bicarbonate (1.685 gr).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of subjects that achieve 'excellent' or 'good' cleansing in the Fleet® Grading Scale for Bowel Cleansing.Time frame: 24 hours
  2. Percentage of subjects who find the agent easy to take or tolerable using a 5 point scale which assesses, the difficulty of taking the product, the degree of discomfort caused by it, and the taste of the drug, recorded in the subject questionnaireTime frame: 24 hours

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • H. Universitari Vall´d Hebron

    Barcelona, Barcelona, Spain

  • H. Clínic

    Barcelona, Barcelona, Spain

  • H. General Universitario Reina Sofía

    Córdoba, Córdoba, Spain

  • H. Universitario Virgen de las Nieves

    Granada, Granada, Spain

  • H. General Universitario Gregorio Marañón

    Madrid, Madrid, Spain

  • H. Universitario Puerta de Hierro

    Madrid, Madrid, Spain

  • H. Infanta Elena

    Valdemoro, Madrid, Spain

  • H. Regional Universitario Carlos Haya

    Málaga, Málaga, Spain

  • H. Universitario Virgen de la Arrixaca

    Murcia, Murcia, Spain

  • Clínica Universitaria de Navarra

    Pamplona, Navarre, Spain

  • H. Universitario Central de Asturias

    Oviedo, Oviedo, Spain

  • H. Virgen Macarena

    Seville, Sevilla, Spain

  • H. Universitario de Canarias

    San Cristóbal de La Laguna, Tenerife, Spain

  • H. Universitario La Fé

    Valencia, Valencia, Spain

  • H. Basurto

    Bilbao, Vizcaya, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.